Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dimebon IR Tablet
Dimebon IR · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Period 1 | EXPERIMENTAL | - |
| Period 2 | EXPERIMENTAL | - |
| Period 3 | EXPERIMENTAL | - |
| Period 4 | EXPERIMENTAL | - |
| Period 5 | EXPERIMENTAL | - |
| Cohort 1 | OTHER | - |
| Cohort 2 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Dimebon IR Tablet | DRUG | Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3. |
| Dimebon MR1 | DRUG | Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3. |
| Dimebon MR2 | DRUG | Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3. |
| Dimebon MR3 | DRUG | Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3. |
| Dimebon MR4 | DRUG | Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3. |
| Dimebon IR | DRUG | A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered. |
| Dimebon Transdermal | DRUG | A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site. |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, p...
Top 20 of 30 competitors
Dimebon IR is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for Alzheimer's disease. It is also known as Dimebon IR Tablet. The program is in Phase 1 clinical development, and both of its recorded Phase 1 trials have been completed.
Dimebon IR is being studied for Alzheimer's disease, a neurological condition. The two completed Phase 1 trials also listed Huntington's disease among the conditions studied. It is investigational and has not been established as a treatment for Alzheimer's disease.
Dimebon IR is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 clinical program for the drug, including the pharmacokinetic and skin absorption studies conducted in the United States.
Dimebon IR is in Phase 1 clinical development. Both of its recorded trials are Phase 1 studies, and both are completed, with no active trials currently listed. It is an investigational drug and is not approved for Alzheimer's disease.
Two completed Phase 1 trials are recorded for Dimebon IR: NCT00990613, which evaluated absorption of a Dimebon solution applied to the skin, and NCT00988624, which estimated the pharmacokinetics of four modified-release formulations of Dimebon (latrepirdine). Both enrolled healthy volunteers in the United States.
Yes. Dimebon IR Tablet is an alternative name for Dimebon IR, so searches for either name refer to the same Pfizer (PFE) investigational small molecule being studied in Phase 1 for Alzheimer's disease.